Choose FABHALTA—a groundbreaking oral monotherapy that helps deliver substantial Hb improvements
in both C5i-experienced and complement inhibitor–naive adults with PNH1
Groundbreaking hemoglobin (Hb) improvements with the first and only FDA-approved oral monotherapy for adults with PNH.1
APPLY primary end points (FABHALTA vs C5 inhibitors [C5is] [eculizumab or ravulizumab]): response rates for sustained Hb increase of ≥2 g/dL: 82.3% (N=62) vs 0% (N=35) with C5is (difference: 81.5; 95% CI, 71.6-91.4; P<0.0001). Response rates for sustained Hb of ≥12 g/dL: 67.7% (N=62) vs 0% (N=35) with C5is (difference: 66.6; 95% CI, 54.6-78.6; P<0.0001). Differences reflect an adjusted difference in proportion
APPOINT single-arm study primary end point: response rates for sustained Hb increase ≥2 g/dL: 77.5% (N=40; 95% CI, 61.5-89.2)
All primary end points were measured in the absence of red blood cell transfusions after 24 weeks
